Thyroid dysfunction during treatment with systemic antineoplastic therapy for childhood cancer (Protocol)

Chantal Lebbink; Eef Lentjes; Wim Tissing; M.M. van den Heuvel-Eibrink; HM van Santen; Elvira C van Dalen

doi:10.1002/14651858.CD013805

Thyroid dysfunction during treatment with systemic antineoplastic therapy for childhood cancer (Protocol)

Chantal Lebbink
, Eef Lentjes
, Wim Tissing
, M.M. van den Heuvel-Eibrink
, HM van Santen
, Elvira C van Dalen

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Objectives
This is a protocol for a Cochrane Review (intervention). The objectives are as follows:

To gain insight into the occurrence of and risk factors for aberrant thyroid function parameters (i.e. TSH, free thyroxine (FT4)) as expression of hypothyroidism, hyperthyroidism, or NTI during cancer treatment in children treated with systemic antineoplastic therapy.

Original language	English
Article number	CD013805
Pages (from-to)	1-9
Number of pages	9
Journal	Cochrane Database of Systematic Reviews
Volume	2020
Issue number	12
DOIs	https://doi.org/10.1002/14651858.CD013805
Publication status	Published - Dec 2020

Access to Document

10.1002/14651858.CD013805

2012 Lebbink_et_al-2020-Cochrane_Database_of_Systematic_ReviewsFinal published version, 121 KBLicence: Taverne

Cite this

@article{4fa69cfa489e438293db388fdc560a09,

title = "Thyroid dysfunction during treatment with systemic antineoplastic therapy for childhood cancer (Protocol)",

abstract = "Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To gain insight into the occurrence of and risk factors for aberrant thyroid function parameters (i.e. TSH, free thyroxine (FT4)) as expression of hypothyroidism, hyperthyroidism, or NTI during cancer treatment in children treated with systemic antineoplastic therapy.",

author = "Chantal Lebbink and Eef Lentjes and Wim Tissing and \{van den Heuvel-Eibrink\}, M.M. and \{van Santen\}, HM and \{van Dalen\}, \{Elvira C\}",

note = "Funding Information: We would like to thank the Editorial Base of Cochrane Childhood Cancer for their advice and support. The Editorial Base of Cochrane Childhood Cancer has been funded by KiKa and is located in the Princess M{\~A}{\^A}¡xima Center for Pediatric Oncology, Utrecht, the Netherlands. We also would like to thank Enrico Brignardello (Transition Unit for Childhood Cancer Survivors, Citt{\~A}{\^A} della Salute e della Scienza Hospital Turin, Italy) and Jonathan D Wasserman (Department of Paediatrics, The Hospital for Sick Children, University of Toronto) for their critical peer review of the protocol. Funding Information: We would like to thank the Editorial Base of Cochrane Childhood Cancer for their advice and support. The Editorial Base of Cochrane Childhood Cancer has been funded by KiKa and is located in the Princess M{\~A}{\^A}¡xima Center for Pediatric Oncology, Utrecht, the Netherlands. Publisher Copyright: Copyright {\textcopyright} 2020 The Cochrane Collaboration. Published by John Wiley \& Sons, Ltd.",

year = "2020",

month = dec,

doi = "10.1002/14651858.CD013805",

language = "English",

volume = "2020",

pages = "1--9",

journal = "Cochrane Database of Systematic Reviews ",

issn = "1469-493X",

publisher = "John Wiley \& Sons Inc.",

number = "12",

}

TY - JOUR

T1 - Thyroid dysfunction during treatment with systemic antineoplastic therapy for childhood cancer (Protocol)

AU - Lebbink, Chantal

AU - Lentjes, Eef

AU - Tissing, Wim

AU - van den Heuvel-Eibrink, M.M.

AU - van Santen, HM

AU - van Dalen, Elvira C

N1 - Funding Information: We would like to thank the Editorial Base of Cochrane Childhood Cancer for their advice and support. The Editorial Base of Cochrane Childhood Cancer has been funded by KiKa and is located in the Princess MÃÂ¡xima Center for Pediatric Oncology, Utrecht, the Netherlands. We also would like to thank Enrico Brignardello (Transition Unit for Childhood Cancer Survivors, CittÃÂ della Salute e della Scienza Hospital Turin, Italy) and Jonathan D Wasserman (Department of Paediatrics, The Hospital for Sick Children, University of Toronto) for their critical peer review of the protocol. Funding Information: We would like to thank the Editorial Base of Cochrane Childhood Cancer for their advice and support. The Editorial Base of Cochrane Childhood Cancer has been funded by KiKa and is located in the Princess MÃÂ¡xima Center for Pediatric Oncology, Utrecht, the Netherlands. Publisher Copyright: Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

PY - 2020/12

Y1 - 2020/12

N2 - Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To gain insight into the occurrence of and risk factors for aberrant thyroid function parameters (i.e. TSH, free thyroxine (FT4)) as expression of hypothyroidism, hyperthyroidism, or NTI during cancer treatment in children treated with systemic antineoplastic therapy.

AB - Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To gain insight into the occurrence of and risk factors for aberrant thyroid function parameters (i.e. TSH, free thyroxine (FT4)) as expression of hypothyroidism, hyperthyroidism, or NTI during cancer treatment in children treated with systemic antineoplastic therapy.

UR - https://www.scopus.com/pages/publications/85103068896

U2 - 10.1002/14651858.CD013805

DO - 10.1002/14651858.CD013805

M3 - Article

AN - SCOPUS:85103068896

SN - 1469-493X

VL - 2020

SP - 1

EP - 9

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

IS - 12

M1 - CD013805

ER -

Thyroid dysfunction during treatment with systemic antineoplastic therapy for childhood cancer (Protocol)

Abstract

Access to Document

Other files and links

Fingerprint

Cite this